Drugmaker with rare disease work · part of Carisma Therapeutics · based in Cambridge, United States · founded 2010 · sesenbio.com
Sesen Bio was a Cambridge, Massachusetts company whose lead drug, Vicineum (VB4-845), was in development for BCG-unresponsive non-muscle invasive bladder cancer. After an FDA complete response letter in August 2021, Sesen paused US development of Vicineum in July 2022, citing the time and cost of another Phase 3 trial. Sesen completed its merger with Carisma Therapeutics on March 7, 2023, and the combined company took the name Carisma Therapeutics.
Sesen Bio Inc clinical trials
We did not find active Sesen Bio Inc trials for the rare diseases we track on ClinicalTrials.gov right now.
More about Sesen Bio Inc
BioSpace and Fierce Biotech reported in April 2025 that Carisma was winding down operations and keeping only 6 staff. Sesen Bio has no active trials or approved drugs.
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Sesen Bio Inc's own site is sesenbio.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Questions about Sesen Bio Inc
Sesen Bio was a Cambridge, Massachusetts company whose lead drug, Vicineum (VB4-845), was in development for BCG-unresponsive non-muscle invasive bladder cancer. After an FDA complete response letter in August 2021, Sesen paused US development of Vicineum in July 2022, citing the time and cost of another Phase 3 trial. Sesen completed its merger with Carisma Therapeutics on March 7, 2023, and the combined company took the name Carisma Therapeutics. BioSpace and Fierce Biotech reported in April 2025 that Carisma was winding down operations and keeping only 6 staff. Sesen Bio has no active trials or approved drugs.
Sesen Bio Inc is a diversified pharmaceutical company headquartered in Cambridge, United States, founded in 2010. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 0 active rare disease programs. Many of its rare disease treatments hold orphan drug designations from the FDA.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Sesen Bio Inc, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
None that we track as of November 2026. No Sesen Bio Inc label in the FDA's openFDA database matches a rare disease on Trial Friend, which usually means the company has no approved product yet or its approved drugs are for common conditions.
In development: the trials list on this page shows what Sesen Bio Inc is recruiting for now, and the FDA calendar lists any application once a decision date is public.
Sesen Bio Inc was founded in 2010 and is headquartered in Cambridge, United States. The company has been active for 16 years. It is a subsidiary of Carisma Therapeutics.